| P50 | author | Glen Hazlewood | Q56797844 |
| P2093 | author name string | L Peyrin-Biroulet | |
| | A N Ananthakrishnan | |
| | G G Kaplan | |
| | E J Mao | |
| P2860 | cites work | Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review | Q22250934 |
| | Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews | Q24289190 |
| | The Cochrane Collaboration's tool for assessing risk of bias in randomised trials | Q27860509 |
| | Meta-analysis in clinical trials | Q27860779 |
| | Crohn's disease | Q28273481 |
| | The burden of inflammatory bowel disease in Europe | Q28285200 |
| | Biologics in inflammatory bowel disease: what are the data? | Q31017419 |
| | The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? | Q34147687 |
| | American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease | Q34387208 |
| | Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin | Q34842148 |
| | Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis | Q35171236 |
| | Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials | Q35557586 |
| | Bayesian methods for evidence synthesis in cost-effectiveness analysis | Q36381197 |
| | Inflammatory bowel disease: a Canadian burden of illness review | Q36391797 |
| | Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis | Q36689512 |
| | The costs of Crohn's disease in the United States and other Western countries: a systematic review | Q37027650 |
| | Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults | Q37035957 |
| | How expensive is inflammatory bowel disease? A critical analysis | Q37335250 |
| | Comparative effectiveness of infliximab and adalimumab for Crohn's disease | Q37445629 |
| | The natural history of adult Crohn's disease in population-based cohorts | Q37622752 |
| | Systematic review: the costs of ulcerative colitis in Western countries | Q37671838 |
| | Review article: remission rates achievable by current therapies for inflammatory bowel disease | Q37842605 |
| | Hospitalisations and surgery in Crohn's disease | Q37977910 |
| | Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis | Q38122070 |
| | Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies | Q38125012 |
| | Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. | Q38186069 |
| | Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease | Q38205873 |
| | Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis | Q38274057 |
| | Trends in hospitalization rates for inflammatory bowel disease in the United States | Q38463339 |
| | Postoperative Mortality Among Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis of Population-Based Studies | Q38521222 |
| | Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. | Q38572827 |
| | History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis | Q40063008 |
| | Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease | Q40722978 |
| | Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. | Q40932469 |
| | Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs | Q41238509 |
| | Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials | Q41822229 |
| | Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis | Q43700990 |
| | Decreasing colectomy rates for ulcerative colitis: a population-based time trend study | Q44097483 |
| | Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study | Q44508235 |
| | Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease. | Q44586150 |
| | Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab | Q44742543 |
| | Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease | Q45329439 |
| | Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. | Q45892140 |
| | The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort | Q47733622 |
| | Direct medical cost of managing IBD patients: a Canadian population-based study. | Q50991301 |
| | Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. | Q51107187 |
| | Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. | Q51739537 |
| | Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study. | Q53196223 |
| | Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis | Q57910344 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Crohn's disease | Q1472 |
| | meta-analysis | Q815382 |
| | immunosuppression | Q1455316 |
| | systematic review | Q1504425 |
| | hospitalization | Q3140971 |
| P304 | page(s) | 3-13 | |
| P577 | publication date | 2016-11-10 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis | |
| P478 | volume | 45 | |